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Research Article
Proteomic analysis of human epithelial
lining fluid by microfluidics-based
nanoLC-MS/MS: A feasibility study
Microfluidics-based nanoLC-MS/MS (chipLC-MS/MS) was used to identify and quan-
tify proteins in epithelial lining fluid (ELF), collected during bronchoscopy from the
main bronchi of chronic obstructive pulmonary disease (COPD) patients and healthy
controls using microprobes. ELF is a biofluid that is well suited to study pathophysiolog-
ical processes in the lung, because it contains high concentrations of biologically active
molecules. 1D-PAGE followed by in-gel tryptic digestion and chipLC-MS/MS resulted in
identification of approximately 300 proteins. A comparative study of ELF from COPD
patients and non-COPD controls using chemical stable isotope labeling (iTRAQ R©-8Plex)
showed that the levels of lactotransferrin, high-mobility group protein B1 (HMGB1), alpha
1-antichymotrypsin and cofilin-1 differed significantly in ELF from COPD patients and
non-COPD controls (p-values< 0.05). These results were reproduced in another, indepen-
dent set of ELF samples fromCOPDpatients and non-COPD controls and further validated
by immunohistochemistry. This study shows the feasibility of performing chipLC-MS/MS
and quantitative proteomics in human ELF.
Keywords:
Chronic obstructive pulmonary disease / Epithelial lining fluid / Mass spectro-
metry / Microfluidics / Proteomics DOI 10.1002/elps.201300020
 Additional supporting information may be found in the online version of thisarticle at the publisher’s web-site
1 Introduction
The prevalence of mortality due to chronic obstructive pul-
monary disease (COPD) is increasing and is expected to rank
as the 3rd cause of death worldwide in 2020 [1, 2]. Major
risk factors for COPD in the western world are smoking or
exposure to tobacco smoke in combination with genetic fac-
tors [3]. The mechanisms that govern COPD initiation and
progression are still poorly understood and no cure is avail-
able for this disease, apart from slowing down progression
by smoking cessation [4]. Moreover, recent evidence suggests
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for advanced glycation end products; ROS, reactive oxygen
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that cigarette smoke accelerates cellular senescence, which
may be implicated in the pathogenesis of COPD [5].
The pathology of COPD encompasses emphysema with
destruction of the lung parenchyma as well as fibrosis of the
small and large airways leading to irreversible airway obstruc-
tion. A subgroup of COPD patients has chronic cough and
sputum production, which is a risk factor for disease severity
[6]. Other factors correlating with disease severity are infiltra-
tion of inflammatory cells, notably lymphocytes, neutrophils
andmast cells, alterations of the bronchial epithelium [7] and
increased thickness of the airway wall [8, 9]. The severity of
COPD is classified in four stages (GOLD stages 1–4) accord-
ing to international guidelines (www.goldcopd.com) based
onmeasurements of lung function (forced expiratory volume
in 1 s percent predicted) but without taking the underlying
inflammatory processes into account. Lung function decline
in mild to moderate COPD is associated with ongoing in-
flammation that flares up when inhaled corticosteroids are
discontinued [7]. The main approaches to treat COPD pa-
tients focus on smoking cessation, symptom relief, physical
activity and reduction of complications such as exacerbations
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Table 1. Characteristics of the COPD patient and non-COPD
control for the proteomics study of ELF by SDS-PAGE
and chipLC-MS/MS
COPD subject Non-COPD subject
Age, years 65 83
Gender Male Female
COPD GOLD stage II No
FEV1,% predicted 70 93
FEV1, forced expiratory volume in 1 s.
[10]. Given the fact that there is no cure for COPD, new bio-
logical markers are required to redefine disease severity and
disease heterogeneity and to assess treatment efficacy [2].
The use of microfluidics-based nanoLC (chipLC) cou-
pled to mass spectrometry has allowed to identify and quan-
tify proteins in minute sample amounts. Proteomic studies
on lung disease have focused on protein analysis in biopsies,
biofluids such as serum, bronchoalveolar lavage fluid (BALF),
sputum or urine and on cells in culture [11–15]. BALF and
sputum are to date the most studied specimens; however,
challenges related to the relative inaccessibility of these sam-
ples from the lung have hampered progress [16]. Drawbacks
of BALF are that it contains not only pulmonary proteins but
is prone to contamination with blood resulting in about 50%
of plasma-derived proteins [16] while sputum has the draw-
back of sampling only the upper airways and of being easily
contaminated with saliva and bacterial proteins. Epithelial
lining fluid (ELF), which forms a thin layer covering the alve-
oli and the mucosa of small and large airways, constitutes the
first barrier between lung tissue and the outer world. ELF,
being an extracellular compartment, contains little DNA or
RNA but high levels of proteins [17] and is an attractive target
for proteomics studies to understand the molecular basis of
COPD, due to its direct contact with cigarette smoke and the
epithelial layer.
ELF can be obtained by bronchoscopic microprobe sam-
pling (BMP), a technique that uses small adsorptive probes
[18, 19]. ELF collected in this way contains higher concentra-
tions of biologically active molecules [20]. Another advantage
of microprobe sampling is that the locations from which ELF
was obtained are clearly defined [18, 21] and it allows collec-
tion of ELF from both central and peripheral airways [22].
In this study, we first provide a qualitative view of the ELF
proteome analyzed by SDS-PAGE followed by in-gel tryptic di-
gestion and chipLC-MS/MS. Subsequently, we describe two
comparative, quantitative studies (Study I and Study II) using
stable isotope labeling (iTRAQ R© Reagent-8Plex) followed by
2D chromatography and MS/MS. Statistical analysis showed
that proteins related to inflammation, infection, host defense
and oxidative stress are differentially expressed in ELF from
COPD patients. To strengthen the proteomics data the cellu-
lar origin of the observed proteins was assessed by immuno-
histochemistry in non-COPD and diseased lung tissue.
2 Materials and methods
2.1 ELF sampling and sample preparation
Epithelial lining fluid was collected from a COPD patient and
a non-COPD subject for the SDS-PAGE experiments (see
Table 1) and from four COPD patients and four non-COPD
controls for Study I and an independent set of four COPD pa-
tients and four non-COPD controls for Study II (see Table 2).
All subjects gave informed consent for the study, which was
approved by the local ethics committee in agreement with the
Helsinki declaration of 1964 as revised in 2004.
Following local anesthesia with 30 mL lidocaine
(2% w/v), a bronchoscope was introduced via the nose or
mouth into the left main bronchus. The outer sheath of
Table 2. Characteristics of the COPD patients and non-COPD controls for the comparative, quantitative proteomics studies of ELF by
iTRAQ R©-8plex labeling
Study I Study II
COPD Non-COPD COPD Non-COPD
(n = 4) (n = 4) (n = 4) (n = 4)
Age, years 67 (47–74) 61.5 (45–83) 60.5 (53–66) 57.5 (20–87)
Female, number 0 2 2 2
Current smoker, number 1 0 1 2
Ex-smoker, number
a)
3 0 3 1
Inhaled corticosteroids, number
b)
2 0 1 0
Co-morbidity, CCI 1.5 (1–4) 0.5 (0–1) 1 (1–3) 0.5 (0–1)
Pack years, number 37.5 (15–60) 0 36.5 (32–45) 3.5 (2.1–31)
FEV1/FVC,% 61.5 (43–68) 75.0 (73–80) 38 (22–51) 84 (70–99)
FEV1,%predicted 74 (44–78) 122 (93–134) 36 (19–70) 119 (68–129)
Values are medians (ranges) or numbers.
a) Years stopped smoking in Study I: COPD patient 1: 20 years; COPD patient 2: 2 years; COPD patient 3: 5 years. Years stopped smoking
in Study II: COPD patient 4: 10 years; COPD patient 5: 9 years; COPD patient 6: 37 years; non-COPD: 35 years.
b) Number of patients and/or controls under treatment with inhaled corticosteroids.
CCI, Charlson co-morbidity index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
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the BMP (BC-401C, BC-402C; Olympus, Tokyo, Japan) was
guided via the working channel of the bronchoscope into the
lumen of the left main bronchus and held at the target posi-
tion. The inner adsorptive tip was pushed out gently till con-
tacting the airwaymucosa and its positionwasmaintained for
10 s allowing ELF adsorption. Participants of the study were
asked not to breath during these 10 s. The tip of the BMP
was subsequently withdrawn into the outer sheath and the
probe was removed from the bronchoscope. This procedure
was repeated to obtain three probes per subject.
The adsorptive tips were cut (about 3 cm in length), in-
serted into 1.5 mL tubes (Greiner, reaction tubes, 1.5 mL,
PP, graduated) containing 1 mL of PBS each and stored
on ice. The tubes were fixed on a slowly rotating wheel for
10 min at 4C to extract proteins. Probes were removed with
the help of tweezers and the extracts were centrifuged (Ep-
pendorf Centrifuge 5417R) for 5 min at 3500 rpm at 4C to
remove insoluble material and divided into 200 L aliquots
(Eppendorf tubes) for storage at −80C.
2.2 Determination of protein concentration
Protein concentration was determined using the Micro BCA
Assay (Pierce Protein Research Product, Thermo Scientific)
following the manufacturer’s protocol in an absorbance plate
reader at 550 nm (Molecular Devices, THERMOmax). The
total protein concentration in the aliquots was between 150
and 400 g/mL.
2.3 Sample preparation for SDS-PAGE
One 200L aliquot of the ELF extract was thawed and concen-
trated five- to ten-fold under vacuum (Eppendorf Concentra-
tor 5301). Concentrated extracts were centrifuged (Eppendorf
Centrifuge 5417R) for 5 min at 5000 rpm to remove insoluble
material. The clear supernatant was transferred to a new tube
and 5 L of five-fold concentrated loading buffer (10% SDS,
10 mM DTT (Sigma), 20% Glycerol (Genfarma bv, Zaan-
dam), 0.2M Tris-HCl, pH 6.8 (Duchefa Biochemie, 0.05%
Bromophenolblue (Bio-Rad)) were added. The samples were
boiled for 3 min prior to SDS-PAGE analysis.
SDS-PAGE was performed in a Mini-Protein III cell
(Bio-Rad) using 12.5% gels with 0.1% SDS according to
the manufacturer’s instructions (all chemicals for polyacryl-
amide gels were from Bio-Rad). PageRulerTM Prestained Pro-
tein Ladder (Fermentas, # SM0671) was used as molecular
weight marker. Proteins were stained with Coomassie Bril-
liant Blue R concentrate (Sigma), diluted and used as rec-
ommended by the manufacturer or with Silver Stain (freshly
prepared) as described [23].
2.4 In-gel digestion
In-gel digestion of proteins was performed according to the
protocol of Shevchenko et al. [24]. Two lanes (one containing
the non-COPD control and one the COPD patient sample)
Figure 1. SDS-PAGE analysis (silver stain) of ELF samples (10 g
of total protein per lane) from a COPD patient (left lane) and
a non-COPD control (right lane). Lanes were cut in 43 (1.5 mm
wide) slices for in-gel digestion and LC-MS/MS analysis.
from a silver-stained gel (Fig. 1) were cut into 43 equal slices
of 1.5 mm width each. Trypsin (Promega, sequencing grade
modified trypsin, # V5111) was used (10 g/mL) for diges-
tion overnight at 37C with shaking at 450 rpm (Eppendorf
Thermomixer). The reactionwas quenched by adding 0.75L
formic acid (FA). The final volume of each sample was about
20 L.
2.5 ChipLC-MS/MS
Proteins were identified after in-gel digestion by nanoLC-
MS/MS using a microfluidics (chip-cube) interface (Agilent,
cat. no. G4240A) including a chip (Agilent, cat. no. G4240–
62002) with a 40 nL enrichment column (75 m × 11 mm)
and a 75 m × 150 mm separation column packed with
Zorbax 300SB (C-18, 5 m) chromatographic material. The
interface contained a nanoelectrospray tip (2 mm length with
conical shape: 100 mod× 8 m id) that was coupled online
to an ion-trap mass spectrometer (MSD-Trap-SL, Agilent).
Injections (3 L) were performed with an autosampler (Agi-
lent, cat. no. G1389A) equipped with an injection loop of 8L
and a thermostated cooler maintaining the samples in the
autosampler at 4C during analysis. The chipLC-MS/MS sys-
tem contained the following additional modules: nanopump
(cat. no. G2226A), capillary loading pump (cat. no. G1376A),
solvent degasser (cat. no. G1379A). Two eluents (eluent A,
0.1% FA in water and eluent B, 0.1% FA in ACN) were used
for the nanopump and one for the capillary pump (0.1% FA,
3% ACN in water). After elution for 5 min with 97% of elu-
ent A, a linear gradient from 3% to 53% of B in 57 min
followed by a step gradient from 53 to 90% of eluent B in
C© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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5 min was run. Ninety percent of eluent B was maintained
for 10 min to regenerate the column.
For acquisition of MS/MS spectra, the following pa-
rameters were used: spray voltage: 1.9 kV, drying gas (N2):
4.0 L/min, dry temperature: 300C, skimmer: 40.0 V, cap.
exit: 200.0 V, Oct. 1: 12.0 V, Oct. 2: 2.50 V, Oct. RF: 200.0 Vpp,
Trap drive: 78.0, Lens 1: −5.0 V, Lens 2: −60.0 V; polarity:
positive, maximal accumulation time: 15 msec, scan from 50
to 2200 m/z, averages: 4, target mass: 622.0 m/z. The orig-
inal MS/MS spectra were analyzed with the Data Analysis
software (Bruker Daltonics, version 3.4). Compounds were
assigned across a retention time window of 18–75 min and
deconvoluted with respect to charge states and isotopes.
2.6 Protein identification after in-gel digestion and
chipLC-MS/MS
MS/MS spectra were exported as Mascot generic files
(Matrix Science, London, UK) and submitted to a web-based
version of Mascot (v2.4) to query the SwissProt database
(release 2012_07, taxonomy “Homo sapiens (human),” 20 232
sequences). The search parameters are listed in Table S4. All
listed proteins were identified based on a minimum of two
unique peptide sequences with p < 0.05 (ions score > 37)
and a maximum false discovery rate of 5% (see Supporting
Information Table 1).
2.7 Stable isotope labeling
ELF samples containing 50 g protein each (about 250–
300 L) were used for iTRAQ R© labeling (see Table 2 for
details about the selected subjects). Samples were diluted
with 5 mL of 10% ACN in 0.1% aqueous trifluoracetic acid
and concentrated by ultrafiltration (Concentrators, Spin 5K
MWCO, 4mL, Part no. 51855991, Agilent). The retentate was
dried under vacuum (Eppendorf Concentrator 5301). After
dissolution in 0.5 M triethylammonium bicarbonate (TEAB)
and denaturation in 2% SDS, reduction with 50 mM tris-(2-
carboxyethyl)phosphine (TCEP) and alkylation with 200 mM
(MMTS), each sample was digested overnight at 37C with
trypsin (Promega, sequencing grade modified trypsin, #
V5111) at an enzyme to protein ratio of 1:6. Subsequently
each sample was labeled (ABSciex, iTRAQ R© Reagent-8Plex)
for 2 h at room temperature according to the manufacturer’s
protocol [25]. Four COPD (labeled with tags 113, 114, 115
and 116, respectively) and four non-COPD control samples
(labeled with tags 117, 118, 119 and 121, respectively) were
labeled. The individually labeled digests were combined into
a single sample mixture of equal original protein amount
of 50 g. In order to remove excess iTRAQ R© reagent and
pre-fractionate to reduce complexity, the peptide mixture was
subjected to strong-cation exchange chromatography (PolyLC
[410 992–5400], 2.1× 200mm column, Columbia, Maryland,
USA) at 0.2 mL/min (AKTA Purifier 10 with frac-900 fraction
collector, GE Healthcare BioSciences AB, Uppsala, Sweden)
using the following buffers: A: 5 mM KH2PO4/H3PO4 pH 3,
25% ACN and B: 5mM KH2PO4/H3PO4 pH 3, 25% ACN,
1.0 M KCl. The gradient was divided into three segments: 0–
15%B [12 column volumes; one column volume corresponds
to 0.69 mL], 15–50% B (3 column volumes), 50–100% B (5
column volumes) at a gradient slope of 10 mMKCl/min. The
resulting peptide-containing fractions (45 out of a total of 60
fractions, 0.2 mL per fraction) were pooled, according to their
UV absorbance at 280 nm to obtain 24 fractions of approxi-
mately equal peptide amount and dried under vacuum in a
centrifuge (Eppendorf Concentrator 5301).
2.8 Comparative protein analysis by LC-MS/MS and
MALDI TOF/TOF
Dried fractions were dissolved in 100 L 2% ACN/0.1%
TFA. Four microliters were trapped on a pre-column
(300 m × 5 mm, C18 PepMap300) and separated on a
C18 capillary column (C18 PepMap 300, 75 m × 150 mm,
3 m particle size) mounted on an Ultimate 3000 nanoflow
LC system (Dionex, Amsterdam, TheNetherlands). Solutions
of 0.05% TFA in water (i) and 80% ACN, 0.05% TFA in water
(ii) were used for elution using a two-step gradient from 4 to
40% B in 50 min and from 40 to 60% B in 10 min at a flow
rate of 300 nL/min. The column effluent was mixed 1:4 v/v
with a solution of 2.3 mg/mL -cyano-4-hydroxycinnamic
acid (LaserBio Labs, Sophia-Antipolis, France) in 60%
ACN/0.07% TFA. Fractions of 12 s were spotted on blank
MALDI targets with a Probot system (Dionex, Amsterdam,
The Netherlands). Mass spectrometric analysis was carried
out on a 4800 Proteomics Analyzer MALDI-TOF/TOF
instrument (Applied Biosystems, Foster City, CA, USA; 4000
Series Explorer v3.5 software) using fixed laser intensity
with a uniformly random spot search pattern. MS data were
acquired automatically over a mass range of 900–5000 Da in
the positive-ion reflector mode. In each MS spectrum the 15
most abundant ions with a signal-to-noise level above 100 and
20 in the m/z range 900–2000 and 2000–5000, respectively,
were selected as precursors for MS/MS fragmentation (2 kV
acceleration voltage; air as collision gas at 4 × 10−7 Torr;
precursor mass window set at 200 resolution (full width at
half maximum); metastable suppression enabled). MS/MS
acquisition was set to a minimum of 1000 and a maximum
of 2000 shots per spectrum with 50 shots per sub-spectrum.
The stop-condition criteria were set to a minimum S/N of
100 on at least seven peaks per spectrum after the minimum
of 1000 shots. Peak lists of the acquired MS/MS spectra were
generated using default settings and a S/N threshold of 10.
Delay time was determined automatically based on the mass
focus (m/z).
2.9 Protein identification and quantification
Proteins were identified based on the acquired peptide
MS/MS spectra using Protein Pilot R© software v2.0 (Applied
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Biosystems). The search was performed against the IPI Hu-
man database (IPI_v3_72, May 2010, 86 417 entries). The
ProteinPilot R© Cutoff score was 1.3, which corresponds to
a confidence limit of 95% at the peptide level. User defined
options were: (i) cysteine alkylation (methyl methanethiosul-
fonate), (ii) trypsin digestion, and (iii) thorough identification
search. The results were exported to Microsoft Excel.
Protein identifications were subsequently confirmed us-
ingMascot (version 2.1, Matrix Science, London, UK) search-
ing against the human sequence database (IPI Human
database, IPI v3_72, May 2010, 86 417 entries) and subse-
quently validated in Scaffold R© version 3.0 (version_3_00_07,
www.proteomesoftware.com). The searchparameters inMas-
cot are listed in Supporting Information Table S5. Protein
identifications were based on at least two unique peptides
identified independently, with a probability higher than 95%
and a false discovery rate of less than 5% at the protein
level.
2.10 Statistical analysis
In order to assess whether there is a statistically significant
difference between protein levels in ELF from COPD pa-
tients versus non-COPD controls, the following approachwas
used:
(i) Calculation of peak areas and determination of the ratios
of the peak areas for all tags.
(ii) Normalization of peak area ratios to iTRAQ-113.
(iii) Transformation of calculated ratios to log10 to approxi-
mate a normal distribution.
(iv) Calculation of p-values of the log-transformed ratios be-
tween COPD and non-COPD control samples for each
peptide using a two-tailed Students t-test.
(v) Exclusion of all peptides with non-significant ratio differ-
ences (p-value > 0.05).
(vi) Visual inspection of reporter ion spectra of significantly
differing proteins and representation of peak areas in the
form of box-and-whisker plots.
2.11 Immunohistochemistry
Immunohistochemistry was performed to compare lung
transplant tissue from five COPD patients (current smok-
ers), five COPD patients (ex-smokers), five non-COPD con-
trols (current smokers) and five non-COPD controls (never
smokers) (see Table 3 for details about patients and controls).
Three-micrometer thick lung sections were cut from selected
formalin-fixed paraffin-embedded tissue blocks andmounted
on to APES (aminopropylethoxysilane)-coated glass slides
(Sigma-Aldrich, Deisenhofen, Germany). Sections were de-
paraffinized (2 × 10 min with xylol, 2 × 100%, 2 × 96%, 1 ×
70% ethanol and 1× rinsed in demineralized water) and sub-
sequently washed in PBS. Antigen retrieval was performed
by microwave treatment for lactotransferrin, high mobility
group protein B1 (HMGB1) and cofilin-1 as follows: after
preheating the solution (1 mM EDTA, pH 8.0) at 100C, the
slides were inserted into a plastic container and heated in a
microwave oven for 15 min at 300 W, cooled in 1 mM EDTA,
pH 8.0 at room temperature and washed three times with
PBS. Antigen retrieval for alpha 1-antichymotrypsin (Ser-
pin A3) was performed in 0.1 M Tris-HCl, pH 9.0 at 80C
overnight. Samples were cooled to room temperature for
30 min and washed with PBS. Endogenous peroxidase ac-
tivity was blocked by incubating the slides for 30 min at
room temperature with 0.3%H2O2 (Merck, Germany) in PBS
(500 L 30%H2O2 in 50 mL PBS). After washing three times
with PBS, sections were incubated with the following pri-
mary antibodies. Cofilin-1: CFL1 monoclonal antibody (M04,
clone 1A1, purified mouse immunoglobulin, H00001072-
M04, Abnova, Taipei, Taiwan). Serpin A3: monoclonal an-
tibody (M04, clone 3F5, purified mouse immunoglobulin,
H00000012-M04, Abnova). HMGB1: monoclonal anti-
body (M03, clone 1B11, purified mouse immunoglobulin,
H00003146-M03, Abnova). Lactotransferrin: monoclonal an-
tibody (clone 1C6, NB120–10109, Novus Biologicals, LLC, Lit-
tleton, CO,USA) diluted 1/100 in PBS containing 1%BSA for
1 h at room temperature. Sections were subsequently washed
three times with PBS and incubated with a peroxidase-labeled
secondary anti-mouse antibody (antiserum raised in rabbits,
DAKO, Glostrup, Denmark, 1/100 diluted in PBS/1% BSA+
1% antiserum) for 30 min at room temperature.
After washing three times with PBS, sections were in-
cubated with peroxidase-labeled goat anti-rabbit antiserum
(DAKO, Glostrup, Denmark, 1/100 diluted in PBS/1% BSA
+ 1%antiserum) for 30min at room temperature. Afterwash-
ing the sections three times with PBS, peroxidase activity was
visualized by incubation with 50mL of 3,3-diaminobenzidine
as substrate in the presence of 50 L 30% H2O2 for 10 min
at room temperature followed by rinsing with demineralized
water. Sections were counterstained with haematoxylin for
approximately 2 min, rinsed in tap water, dehydrated in 70,
96 and 100% ethanol and then dried. Finally sections were
mounted with mounting medium and covered with a cover
slip.
A semi-quantitative analysis for cofilin-1 was performed
in a blinded fashion by two persons (ML and LF). The 20
stained tissue sections were scored based on staining in-
tensity on a scale from 0 to +3 (0 = negative; +1 = weak;
+2 = positive; +3 = strongly positive). In case of uncertainty
on the level of staining a score of 0.5 was assigned.
3 Results
3.1 ELF analysis by SDS-PAGE and chipLC-MS/MS
To map the ELF proteome, samples from a COPD patient
and a non-COPD control were subjected to protein separa-
tion by SDS-PAGE (Fig. 1). Forty-three bands from each lane
were cut, subjected to trypsin digestion and subsequently an-
alyzed by chipLC-MS/MS resulting in a total of 269 identified
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Table 3. Characteristics of subjects for immunohistochemistry in lung tissue
COPD current smokers COPD ex-smokers Non-COPD current smokers Non-COPD never smokers
(n = 5) (n = 5) (n = 5) (n = 5)
Female, number 0 0 4 4
Age, years 69 (44–72) 72.5 (65–76) 65 (58–68) 65 (36–70)
Pack years, number 36 (27–58) 30 (8–50) 25 (13–38) 0
Stop smoking, years 0 17 0 0
FEV1,% predicted 75.5 (50–78) 67 (50–74) 91 (76–118) 114 (101–127)
Values are medians (ranges), or numbers.
FEV1, forced expiratory volume in 1 s.
proteins (1349 peptides) of which 193 were identified in both
ELF samples. Analysis of the ELF sample from the COPD
patient resulted in 239 identified proteins while 223 proteins
were identified in the non-COPD control sample. Forty-six of
the 269 proteins were only identified in the COPD sample,
while 30were only identified in thenon-COPDcontrol sample
(see Supporting Information Table 1). Annotation of proteins
that were only identified in ELF from the COPD patient re-
vealed a set of potentially interesting functions. A member of
the nicotinic acid-related structural protein family (nicotinate
phosphoribosyltransferase, accession number Q6XQN6 and
nicotinamide-phosphoribosyltransferase, accession number
P43490) that is related to the host response to bacterial infec-
tions was identified. The presence of protein S100A8 (acces-
sion number P05109), a member of the calgranulin super-
family [26], may reflect the chronic inflammation associated
with COPD development and progression. Presence of the
enzyme leukotriene A-4 hydrolase (LTA-4hydrolase, acces-
sion number P09960) [27] indicates a key role of oxidative
stress in COPD, while glutathione S-transferases A2 (acces-
sion number P09210), A3 (accession number Q16772) and
theta-1 (accession number P30711) [28], detoxifying enzymes
that protect against oxidative stress, were only identified in
ELF from the non-COPD control.
ELF from the COPD patient contained a number of Ras-
related proteins (RAB1B, RAB10, RAB35; accession num-
bers P62820 or Q9H0U4, P61026 and Q15286, respectively).
This may indicate involvement of EPAC proteins in obstruc-
tive airways diseases [29] and their anti-inflammatory effect
in alveolar macrophages [30, 31]. Many proteins involved in
proteasome activation and regulation (Proteasome activator
complex subunit 3 and proteasome subunit beta type-4; ac-
cession numbers P61289 and P28070, respectively) were only
identified in ELF from the COPD patient, a result that points
towards the involvement of the proteasome during conditions
of inflammation and oxidative stress.
Although most of the tubulin protein family mem-
bers were identified in ELF from the COPD patient and
the non-COPD control (TBA1B, TBA1A, TBB5, TBA1C,
TBB2A, TBB3, TBA8; accession numbers: P68363, Q71U36,
P07437, Q9BQE3, Q13885, Q13509, Q9NY65, respectively),
some types such as TBB2B and TBA4A (accession numbers:
Q9BVA1 and P68366, respectively) were not detected in ELF
from the COPD patient.
3.2 Comparative quantitative proteomics using
iTRAQ R© labeling
Shotgun proteomics with stable isotope labeling using the
iTRAQ R© 8-plex reagents and MALDI-TOF/TOF MS lead to
the identification of 138 proteins based on 1745 iTRAQ R©-
labeled peptides with a confidence level of >95% for Study
I, and 161 proteins (1205 iTRAQ R©-labeled peptides with a
confidence level of>95%) for Study II (see Supporting Infor-
mation Tables 2 and 3).
Each study resulted in a number of proteins with sta-
tistically significantly different concentration levels in ELF
between COPD patients and non-COPD controls (see Sup-
porting Information Tables 6 and 7). The levels of four
proteins, lactotransferrin (accession number P02788), alpha
1-antichymotrypsin (accession number P01011), cofilin-1 (ac-
cession number P23528) and HMGB1 (accession number
P09429), were significantly different (p<0.05) in both studies.
The protein sequence selected for quantification was
based on unique peptides identified in both studies. In par-
ticular, 13 unique peptides were identified for lactotransfer-
rin, three for HMGB1, four for cofilin-1 and two for alpha
1-antichymotrypsin in Study I.
In Study II, 21 peptides for lactotransferrin, four
for HMGB1, four for Cofilin-1 and three for alpha
1-antichymotrypsin were identified, respectively.
Some of the peptides were redundantly identified, but
only unique peptides specific for that protein with p <0.05
and confidence of identification >95% were selected for the
final quantification.
Lactotransferrin was increased in ELF of COPD pa-
tients (Fig. 2A and B) based on the analysis of two unique
peptides that were found in Study I and Study II (QVLL-
HQQAK and CVPNSNER). Comparative sequence analysis
using Scaffold R© established that there is no ambiguity with
respect to other proteins belonging to the same superfamily,
such as serotransferrin. The increase in lactotransferrin may
be related to its antimicrobial properties [32]. In fact it has
been demonstrated that secretion of antimicrobial proteins
by epithelial cells is increased upon airway inflammation,
which supports our findings [33]. A search against a sequence
database covering eubacteria excluded the possibility that this
protein was of bacterial origin (data not shown). Although not
statistically significant in Study I, we also found lysozyme C
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Figure 2. Box and whisker
plots of the levels of three
proteins that differed signif-
icantly in ELF from COPD
patients versus non-COPD
controls in two independent
studies (Study I and Study II).
Lactotransferrin ((A) Study I,
peptide QVLLHQQAK and (B)
Study II, peptide CVPNSNER);
HMGB1 ((C) Study I, peptide
GKFEDMAK and (D) Study II,
peptide GKFEDMAK); Serpin
A3 ((E) Study I, peptide
ADLSGITGAR and (F) Study
II, peptide ADLSGITGAR).
Each error bar represents the
variation inside the group (see
Supporting Information Table
7).
(a protein of the innate immune system that also exhibits
antibacterial properties) to be increased in ELF from COPD
patients (p < 0.05 in Study II) based on three unique pep-
tides (GISLANWM, TPGAVNACHLSC and WESGYNTR).
Immunohistochemistry (IHC) of lactotransferrin revealed a
strong positive staining in glands in lung tissue from COPD
patients and non-COPD controls (see Supporting Informa-
tion Fig. 1) indicating that higher levels of lactotransferrin in
ELF are likely due to increased secretion by epithelial cells in
COPD patients.
Our analyses (Study I and Study II) showed that HMGB1
is reduced in ELF of COPD patients relative to non-COPD
controls (Fig. 2C and D), which contrasts with an earlier
study in BALF of COPDpatients [34]. Analysis with Scaffold R©
showed that the selected peptides were specific for HMGB1,
excluding a possible affiliation with similar proteins such
as HMGB2. Immunohistochemical analysis of lung tissue
from COPD patients and non-COPD controls (current, ex
and never smokers) showed that HMGB1 is mainly present
in the nuclei of epithelial cells and macrophages without vis-
ible differences in abundance (see Supporting Information
Fig. 2). HMGB1 is thus likely released into ELF due to leak-
age from epithelial cells associated with necrosis and cellular
turnover.
The alpha 1-antichymotrypsin (Serpin A3) level was in-
creased in ELF from COPD patients (Fig. 2E and F) in both
studies. Since immunohistochemistry of lung tissue showed
protein expression in alveolar macrophages (high levels) as
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Figure 3. Box and whisker plots of the levels of cofilin-1. (A) Study I, peptide VFNDMK and (B) Study II, peptide CTLAEK. (C) Box
and whisker plots of the levels of cofilin-1 in ELF of smokers (current and past) and never-smokers (peptides VFNDMK and CTLAEK,
respectively). Each error bar represents the variation inside the group (see Supporting Information Table 7).
Figure 4. Immunohistochemistry of cofilin-1 in lung tissue from (A) a COPD patient (current smoker), (B) a non-COPD control (never-
smoker) and (C) a non-COPD control (current smoker), (D) and (E) are negative staining controls.
well as in epitheliumand endothelium (moderate levels)with-
out visible differences in abundance in lung tissue from
COPD patients and non-COPD controls (current, ex and
never smokers) (see Supporting Information Fig. 3), we con-
clude that secretion of alpha-1-antichymotrypsin is increased
in COPD patients.
Remarkably, elevated levels of cofilin-1 were present in
ELF from COPD patients in Study I (Fig. 3A), while they
appeared to be decreased in Study II (Fig. 3B). Comparative
sequence analysis using Scaffold R© established that there is
no ambiguity with respect to other proteins. These, at first
sight, contradictory results, were reconciled when taking the
smoking history of the subjects into account. The ELF con-
trol samples used in Study I where all from never-smokers
(see Table 2), while two of the controls in Study II were cur-
rent smokers and one was an ex-smoker, although without
COPD. When reclassifying our samples into smokers (cur-
rent and past) and never-smokers, we found that cofilin-1
is significantly increased in ELF from smokers, irrespective
of them having COPD (Fig. 3C). These results were con-
firmed by immunohistochemistry (Fig. 4). In fact, a semi-
quantitative, blinded immunohistochemical analysis of lung
tissue from current smokers with or without COPD showed
increased staining compared with non-COPD controls who
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Figure 5. Semi-quantitative scoring of staining intensity of the
immunohistochemical analysis of cofilin-1 in lung tissue. COPD
curr = COPD patients (current smokers); COPD ex = COPD pa-
tients (former smokers); Ctrl curr = non-COPD controls (current
smokers); Ctrl non = non-COPD controls (never smokers). Each
dot represents a single patient or control. All analyses were per-
formed by two independent investigators in a blinded fashion
(ML and LF).
never smoked (Fig. 5). This corroborates previously published
data showing that cofilin-1 is increased in lung tissue of non-
COPD smokers [26].
The reproducibility of the quantification for the chosen
peptides was confirmed for all the selected proteins (coeffi-
cient of variation of the peptide area ratios< 1; see Supporting
Information Table 9).
4 Discussion
4.1 ELF proteomics by SDS-PAGE and
chipLC-MS/MS
This is thefirst detailed proteomics study of humanELFbased
on chipLC-MS/MSwith a focus on deciphering changes at the
proteome level that are related to COPD. Proteomic analysis
of ELF by SDS-PAGE followed by in-gel digestion and chipLC-
MS/MS resulted in identification of 269 proteins in samples
from COPD patients and non-COPD controls. The identi-
fied proteins (see Supporting Information Table 1) belong to
families that are involved in various aspects of COPD
pathogenesis, such as inflammation, oxidative stress, bac-
terial infection, the acute-phase response and the protease-
antiprotease balance [35].
A potent antioxidant system in the airways is based on
glutathione (GSH). It has been shown that alterations in the
balance betweenGSSG, the oxidized form of glutathione, and
its reduced form (GSH) are related to oxidative stress in lung
epithelial cells and that exposure to cigarette smoke decreases
the levels of intracellularGSH [36]. It is interesting tonote that
GST A1, A2, A3 and theta-1 were only identified in ELF of the
non-COPD control [37]. Our finding corroborates published
data showing increasedGST gene expression in the bronchial
epithelium of smokers without COPD [28], polymorphisms
that associate with COPD development [38] and the effect of
cigarette smoke on this important regulatory enzyme family
[39].
One protein of the S100 family, S100A8, was only identi-
fied in ELF from the COPD patient. S100 proteins are known
to be expressed in epithelial cells and macrophages during
chronic inflammation and to be released by phagocytes, after
interaction with microtubules, exhibiting pro-inflammatory
activity [40]. The identified S100 proteins belong to the cal-
granulin subgroup known to contribute to experimental and
clinical lung inflammation with an elevated concentration
in the cytoplasm of neutrophils. Release of calgranulins from
neutrophils upon activation is related to their antibacterial ac-
tivity [41]. Their over expression at sites of inflammation [42]
and their action as “amplifiers” of inflammation, affecting
cytokine induction, underline a possible role in the develop-
ment of COPD. Calgranulins may thus constitute important
therapeutic targets to modulate inflammation [43, 44].
The qualitative proteomics study revealed the presence of
proteasome-related proteins in ELF from the COPD patient.
The 26S proteasome has been shown to exist outside the cell
(after lung injury) and to contribute to proteolysis of proteins
in the alveolar space. Furthermore, it has been demonstrated
that the ubiquitin-proteasome system plays a crucial role in
maintaining homeostasis of muscle tissue in response to hy-
poxemia as well as during inflammation and oxidative stress
[45, 46].
Some members of the tubulin family (TBB2B and
TBA4A), a class of GTP-binding proteins that are the ma-
jor constituents of microtubules, were only detected in ELF
from the non-COPD control. The interaction between tubu-
lins and actin filaments is fundamental for the structure of
the cytoskeleton and the induction of cytoskeletal changes. It
is of importance to note that cofilin-1, another actin-binding
protein, was found to be increased in ELF of current or past
smokers (see below), indicating that exposure to cigarette
smoke can influence the rearrangement of the cytoskeleton.
4.2 Quantitative ELF proteomics using iTRAQ
labeling
Chemical stable isotope labeling (iTRAQ R© 8-plex) in com-
bination with two-dimensional liquid chromatography and
MALDI-TOF/TOF mass spectrometry allowed assessing dif-
ferential protein levels when comparing ELF from COPD
patients versus non-COPD controls. Comparison of the ELF
proteome in Study I (fourCOPDpatients and four non-COPD
controls) and Study II (a different set of four COPD patients
and four non-COPD controls) showed that lactotransferrin,
cofilin-1, HMGB1 and alpha 1-antichymotrypsin (serpin A3)
were significantly different.
Lactotransferrin, an iron-binding protein that is signifi-
cantly increased in ELF from COPD patients, has bactericidal
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and bacteriostatic properties, giving it a major role in the
first-line defense against microbial infections and in the pre-
vention of systemic inflammation. Immunohistochemistry
of lung tissue from COPD patients showed that lactotrans-
ferrin is primarily expressed in submucosal glands as well
as in serous and acinar cells (see Supporting Information
Fig. 1). Lactotransferrin is present in different secretory flu-
ids (e.g. milk, saliva, and nasal secretions) and is, together
with lysozyme C, the most abundant antimicrobial protein
in human airways [32]. Previous studies have demonstrated
higher concentrations of these two proteins in the airways of
patients suffering from cystic fibrosis as well as in patients
with COPD, asthma, chronic bronchitis, and pneumonia [32].
Lactotransferrin kills bacteria by binding iron with very
high affinity, which is essential for survival of bacteria and
for stabilization of the bacterial membrane, explaining the
increased levels in COPD patients, where a continuous in-
flammatory process is ongoing rendering patients suscepti-
ble to bacterial infections. The capability of lactotransferrin
to scavenge free iron ions is also important for development
of the adaptive immune response as well as for the reduction
of oxidative stress, since metal ions catalyze the generation of
free radicals [28, 47]. Recently, it has been proven that free
iron ions may be involved in the pathogenesis of airways
disease, notably COPD and asthma [35]. Interestingly, lacto-
transferrin binds to lipopolysaccharide (LPS) with high affin-
ity, thus preventing its association with other LPS-binding
proteins and blocking the transfer of LPS to the CD14 re-
ceptor on the surface of macrophages [48]. Lactotransferrin
exhibits anti-inflammatory activity through this mechanism
by down-regulating the release of cytokines from monocytes
and reducing recruitment and activation of immune cells at
inflammatory sites [49–51].
Alpha 1-antichymotrypsin (Serpin A3), a member of the
acute-phase protein family, was shown to be increased in ELF
from COPD patients (Fig. 2E and F). Immunohistochemistry
of lung tissue showed that this protein was primarily and ex-
tensively present in alveolarmacrophages as well as in epithe-
lium and endothelium (see Supporting Information Fig. 3).
The plasma concentration of alpha 1-antichymotrypsin can
increase up to 100-fold during inflammation or infection
induced by cytokines. This serine proteinase inhibitor, that
principally targets cathepsin G, is also involved in the inflam-
matory response associated with tumor growth and invasive-
ness and there is evidence that it can be produced by lung ade-
nocarcinomas [52]. Even though alpha 1-antichymotrypsin is
primarily produced in the liver, there is evidence of its secre-
tion from alveolar epithelial cells and alveolar macrophages
[53, 54].
HMGB1, amember of the class of “alarmins,” is not only
aDNA-bindingprotein but has also been shown to be involved
in the development and progression of acute lung injury. Dif-
ferent studies [55] demonstrated its pro-inflammatory activity
by binding to cytokines such as IL-1 and TNF-. It was sur-
prising to find that in our studies the level of HMGB1 was
increased in non-COPD controls (Fig. 2, panels C and D) in
contrast to published data on BALF from COPD patients [34].
Our quantitative results are based on the analysis of three
peptides, one of which (GKFEDMAK) overlapped between
the two studies. Analysis with Scaffold R© showed that the
selected peptides were specific for HMGB1, excluding a pos-
sible affiliation with similar proteins such as HMGB2. Since
our quantitative results were reported as ratios with respect
to the 113 label, we verified the influence of normalization on
the final result by repeating the data analysis with normaliza-
tion to each of the other seven labels (data not shown). This
confirmed that normalization did not affect the overall result
showing an increased level in ELF from non-COPD controls
as compared to COPD patients. Further studies are required
to address this apparent discrepancy.
Extracellular HMGB1 is one of the main diffusible sig-
nals of necrosis. HMGB1 binds to the receptor for advanced
glycation end products (RAGE) with high affinity, while it
remains tightly bound to DNA during apoptosis [56]. Im-
munohistochemistry of lung tissue showed that HMGB1 is
localized in the nuclei of epithelial cells indicating that its
presence in ELF is due to release from these cells (see Sup-
porting Information Fig. 2). It is noteworthy that the function
ofHMGB1may be altered by post-translationalmodifications
(acetylation, phosphorylation, oxidation andmethylation) that
can, for example, affect the binding to RAGE. The differential
occurrence of modifications may provide one possible expla-
nation for the conflicting findings obtained by quantitative
proteomics in ELF (this study) and those reported by others
using ELISA assays in BALF [34]. Taking the pluripotency of
HMGB1 into account, its interaction with different types of
receptors (not only RAGE, but also toll-like receptor) and its
involvement in a range of signaling pathways, it is important
to keep in mind that this protein alone has only minimal
pro-inflammatory activity [57, 58].
Cofilin-1, a protein that we found to be increased in ELF
and lung tissue from smokers (current and past), irrespective
of COPD, is an actin depolymerizing factor, mainly involved
in cytoskeletal changes and is themajor formof cofilin in non-
muscle tissue. After binding to cofilin, actin is converted into
its active monomer and transported to the nucleus, where it
can activate RNA polymerase II and promote gene transcrip-
tion [59]. Cofilin-1 is found in association with actin rods
during cellular stress, in the nucleus or in the cytoplasm,
and protects actin until the stress is over [60]. Previous data
show that the levels of active cofilin and ADP-actin increase
dramatically in response to oxidative stress due to an ele-
vated level of reactive oxygen species (ROS) and a decline
in ATP levels resulting in the formation of cofilin-actin rods
[61]. It is thus important to maintain the level of ATP above
a certain threshold in order to allow a cell to recover. In
this balance the contribution of cofilin-1 is essential, because
a large amount of active cofilin can be sequestered by the
rods thus reducing depletion of ATP, since ATP hydrolysis
is associated with actin turnover, which is in turn promoted
by cofilin [61]. Klemke et al. showed the link between the
formation of oxidized cofilin and oxidative stress, by direct
incubation of the protein withH2O2 [62]. Oxidized cofilin, de-
spite its binding to F-actin, was no longer capable to promote
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depolymerization, creating a link between oxidative stress
caused by ROS and cellular hyporesponsiveness. Recently, a
phosphorylated (on Ser3) inactive form of cofilin-1 was found
in response to ROS, further emphasizing the influence of
stress factors, such as exposure to tobacco smoke, on the
regulation of cellular functions by cofilin.
Our study of human ELF shows the power of combin-
ing different methods (microfluidics-based nanoLC-MS/MS,
iTRAQ R© labeling and immunohistochemistry) to compare
expression levels of different proteins in samples of limited
availability and to elucidate their localization in lung tissue.
Due to the limited number of patients and controls and the
lack of well-matched COPD and non-COPD samples, this
should be considered a pilot study that requires verification in
larger sample sets. Our study demonstrates the feasibility of
proteomics investigation in human ELF and represents a first
approach to perform quantitative studies on pulmonary dis-
eases using this biofluid. Despite their exploratory character,
our results show the possibility to identify proteins related to
biological or clinical features of COPD, underlying the power
of combining the novelty of using ELF and different analytical
methods of analysis.
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